CIK 0001782223 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Pyxis Oncology, Inc.
Sign in to watch- Ticker
- PYXS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 831160910
- Phone
- (617) 221-9059
- Business address
- 321 HARRISON AVENUE, BOSTON, MA, 02118
- Open-market buys, last 90 days
- $0
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 4 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-06 | HUMPHREY RACHEL Director | Grant or award · Stock Option (Right to Buy) | +34,500 | 34,500 | ||
| 2026-10-01 | GordonMD Global Investments LP 10% owner | Purchase · Common Stock Purchase Warrant | +7,172,000 | 7,172,000 | ||
| 2026-10-01 | GordonMD Global Investments LP 10% owner | Purchase | +5,517,000 | 15,541,909 | ||
| 2026-10-01 | GordonMD Global Investments LP 10% owner | Purchase · Common Stock Purchase Warrant | +7,546,766 | 7,546,766 | ||
| 2026-09-04 | Civik Thomas CEO & Chairman of the Board | Grant or award · Stock Option (Right to Buy) | +2,503,050 | 2,503,050 | ||
| 2026-08-20 | Dupont Jakob Director | Grant or award · Stock Option (Right to Buy) | +46,000 | 46,000 | ||
| 2026-08-12 | Civik Thomas Interim CEO | Grant or award · Stock Option (Right to Buy) | +250,956 | 941,087 | ||
| 2026-06-30 | Dupont Jakob Director | Option exercise 10b5-1 | +35,000 | $1.60 | $56K | 73,741 |
| 2026-06-30 | Dupont Jakob Director | Sale 10b5-1 | −35,000 | $3.06 | $107K | 38,741 |
| 2026-06-30 | Dupont Jakob Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −35,000 | 357,461 | ||
| 2026-03-24 | Dupont Jakob Director | Grant or award · Stock Option (Right to Buy) | +45,867 | 45,867 | ||
| 2026-03-24 | Wadhane Jitendra Prin Fin & Acct Officer | Grant or award | +109,461 | 512,882 | ||
| 2026-03-24 | Wadhane Jitendra Prin Fin & Acct Officer | Grant or award · Stock Option (Right to Buy) | +262,635 | 262,635 | ||
| 2026-03-24 | FLAVIN JOHN L Director | Grant or award · Stock Option (Right to Buy) | +45,867 | 45,867 | ||
| 2026-03-24 | Metzger Michael A Director | Grant or award · Stock Option (Right to Buy) | +45,867 | 45,867 | ||
| 2026-03-24 | Lewis-Hall Freda C Director | Grant or award · Stock Option (Right to Buy) | +45,867 | 45,867 | ||
| 2026-03-24 | Cline Darren S Director | Grant or award · Stock Option (Right to Buy) | +45,867 | 45,867 | ||
| 2026-03-24 | HUMPHREY RACHEL Director | Grant or award · Stock Option (Right to Buy) | +45,867 | 45,867 | ||
| 2026-03-24 | Palani Santhosh Director | Grant or award · Stock Option (Right to Buy) | +45,867 | 45,867 | ||
| 2026-02-03 | Civik Thomas Interim CEO | Grant or award · Stock Option (Right to Buy) | +690,131 | 690,131 |
Page 1 of 7 · 137 trades